Clinical trials located in

Gera

Gera city is located in Germany. Currently, 11 clinical trials are being conducted in this city.

Gera, located in Thuringia, Germany, is renowned for its rich cultural heritage and historical architecture. Founded in the 10th century, it became a significant textile industry hub by the 19th century. The city is the birthplace of the famous painter Otto Dix, and it houses the Otto Dix House museum, dedicated to his life and work. Gera’s extensive network of underground tunnels, built for beer storage in the 17th century, adds a unique aspect to its historical landscape. The city also boasts the Gera Zoo and the Hofwiesenpark, reflecting its commitment to natural beauty and conservation.

  • CT-EU-00117573

    Study of Combination Therapy for Melanoma After Anti-PD-1 Treatment

    This clinical trial is comparing two different treatment approaches for advanced melanoma, which is a type of skin cancer that has spread to other parts of the body. If you have a specific gene mutation called BRAF and have previously received treatment with certain immunotherapy drugs like nivolumab or pembrolizumab, you may be eligible for this study.

    One treatment approach involves receiving three study medicines: pembrolizumab given through an IV every 3 weeks, along with encorafenib and binimetinib taken by mouth daily at home. The other approach involves receiving two study medicines: ipilimumab and nivolumab given through an IV every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatment approaches will be given for around 2 years, but there is no time limit for the encorafenib and binimetinib treatment.

    The study team will closely monitor your condition during regular visits to the clinic to see how you are responding to the treatment. The main goal is to determine which treatment approach is more effective in shrinking or eliminating the melanoma tumors. Around 150 participants will be enrolled in this study and randomly assigned to one of the two treatment groups.

    CzechiaGermanyItalyPolandSlovakiaSpainUnited Kingdom
  • A Study Comparing ABP 206 and Nivolumab for Resected Melanoma

    This here clinical trial is aimin’ to see if a new drug called ABP 206 works just as good as the approved cancer drug OPDIVO® (nivolumab) for folks with advanced melanoma skin cancer that’s been removed by surgery. The study is splittin’ folks into 3 groups, with one group gettin’ ABP 206, another gettin’ the real OPDIVO® approved in the U.S., and the third gettin’ the version of OPDIVO® approved in Europe. All these drugs will be given through an IV drip every 4 weeks for up to 1 year, or until the cancer comes back or gets too bad.

    The main goal is to check if ABP 206 gets absorbed and stays in the body the same way as OPDIVO®. They’ll also be keepin’ a close eye on how well it works, any side effects, and if the body makes antibodies against it. The whole study will last around 13 months for each person joinin’. It’s a double-blind study, meanin’ neither the folks gettin’ the drugs nor the doctors givin’ ’em will know which one they’re gettin’ until the end.

    FranceGermanyItalyNetherlandsRomaniaSpain
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    BelgiumDenmarkFranceGermanyGreeceItalyPolandPortugalSpainSwedenUnited Kingdom
  • Study on the impact of tavapadon on Parkinson’s disease

    This trial is designed to assess a potential treatment for early Parkinson’s disease known as tavapadon. The study spans 27 weeks, during which participants will receive either the actual drug or a placebo (substances without pharmacological effect) in a randomized manner, with neither the individuals nor the researchers knowing who receives which. Parkinson’s disease symptoms will be monitored using a 0-4 scale, where 0 indicates normal and 4 reflects severe impairment across various aspects of daily living and movement. Both the doctor and the participant will assess and score the symptoms and improvements.

    The trial will also include an evaluation of the participant’s personal assessment of change since the start of treatment. Respondents will indicate how much their condition has changed, ranging from very much improved to very much worse. Researchers will additionally examine situations where the participant may feel sleepy, such as reading or sitting in a car for an extended period without a break, scoring between 0 and 3 based on the likelihood of dozing off. The study will monitor potential impulse control disorders, and any side effects or health issues attributable to the treatment.

    FranceGermanyHungaryItalyPolandSpain
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Discovering a new drug for atopic dermatitis

    This clinical trial aims to evaluate the safety and effectiveness of LEO 138559, a new medication for adults with moderate-to-severe atopic dermatitis, a challenging skin condition. The study tests four different doses of LEO 138559 against a placebo (a treatment without the active drug) over 36 weeks. Participants, who will be randomly assigned to one of the doses or placebo, will receive injections just under the skin at regular clinic visits. The trial includes a 4-week screening phase, a 16-week treatment phase, and a 16-week follow-up. Participants will visit the clinic 17 times and keep a daily electronic diary to track their skin condition and quality of life. This study is crucial for understanding how well LEO 138559 works and its safety in treating this persistent skin condition.

    CzechiaFranceGermanyPolandRomaniaSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Comparison of different treatment methods for muscle-invasive bladder cancer

    This trial is designed for patients with muscle-invasive bladder cancer who are either unable to use or decline the use of cisplatin – a commonly used chemotherapy drug. The trial evaluates two treatment methods: surgery alone (cystectomy), and surgery combined with the medications pembrolizumab and/or enfortumab vedotin. The combination therapies happen before and after the surgery. The primary aim is to compare the event-free survival (EFS), meaning time without disease progression or death, in these different approaches. It’s important for potential participants to know they will be randomly assigned a method of treatment for comparison. Medical exams and tests will be conducted to ensure patient safety and monitor progress.

    BelgiumDenmarkFranceGermanyHungaryItalyPolandSpainSwedenUnited Kingdom

See more clinical trials in other cities in Germany:

.